| Literature DB >> 19713109 |
Amogh Boloor1, Denise Hanway, Maria Joshi, David T Winn, Gabriel Mendez, Marlena Walls, Ping Wei, Fuxin Qian, Xiaoli Zhang, Yuliang Zhang, Michael E Hepperle, Xinqiang Li, David A Campbell, Juan M Betancort.
Abstract
A new series of NS3/4A protease boronic acid inhibitors is described. The compounds show good biochemical potency and cellular activity. The peptidomimetic inhibitors were evaluated against proteases from different HCV genotypes and clinically relevant NS3/4A mutants. Compound 28 displayed subnanomolar to single digit nanomolar potencies in the enzymatic assays and an EC50 of 25 nM in the replicon cell-based assay.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19713109 DOI： 10.1016/j.bmcl.2009.08.017
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823